RK Smiley Research Grant Program

Dr. R. Kennedy Smiley

Since 2011 CHS has provided a member(s) with the RK Smiley Research Grant.  This start-up grant is aimed at pilot projects expected to lead to larger follow-up studies funded by CIHR or other grant funding agencies.  This award is named in honour of the CHS Founding President, Dr. R. Kennedy Smiley, who was also instrumental in founding the University of Ottawa’s medical school.


Deadline to apply: March 15th each year

Decision made in May.


Eligibility Criteria:

  • Principal investigator must be a CHS member in good-standing
  • May be clinician or scientists with a project relevant to the field of hematology
  • Principal investigator on the application should be able to hold grant at their institution

Important Award information

Project length is two-years from date of approval.  For example, approval was 5/15/2023 and therefore project end date is 5/15/2025.

Only one application will be received per applicant in a given year.

Preference given to groups who will benefit maximally from the start-up grant.

Be prepared! Online application requires information on project background, relevance to the field of hematology, a budget, methodology, CV upload and explanation of how the award impacts a career, what mentorship is available and/or how trainees will be engaged.

Award winners will receive the $20,000 CDN grant in two installments: first installment upon notification of winning the grant.  The grant recipient must provide an update to the CHS Board at the one-year mark of the project.  If the update is sufficient the second payment will be issued.  At the end two-years the grant recipient must be prepared to submit a report that includes:


  • Abstract highlighting progress/accomplishments for this project
  • Limitations/challenges faced
  • Budget summary (what funds were spent on; what funds remain)
  • KT activities/plan
  • Next steps (including future funding applications)


Grant recipients must acknowledge the funding from CHS in any publication.


RK Smiley Research Grant Winners


  • 2022

    Dr. Stéphanie Forté

    PULSE: a study evaluating the brain pulsatily index as a biomarker for neurovascular complications in adults with sickle cell disease

    Associate Professor, University of Montreal


  • 2021

    Dr. Mark McVey

     Investigation of Adiponectin’s role in Regulating Transfusion-Related Acute Lung Injury

    University of Toronto

  • 2021

    Dr. Syed Qadri

    Deciphering the impact of acute intermittent hypoxic training on red blood cell functions: Implications in red blood cell transfusion

    Ontario Tech University


  • 2020

    Dr. Clinton Campbell

    DEEPHEME: An Innovative Deep Learning Platform to Improve Diagnosis in Hematology

    McMaster University

  • 2020

    Dr. Courtney Jones

    Identification of Glutathionylated Proteins in the Mitochondria of Leukemia Stem Cells

    Unity Health Network


  • 2019

    Dr. Miriam Kimpton

    Thromboprophylaxis with apixaban in polycythemia vera and JAK2- positive essential thrombocythemia patients: A pilot randomized controlled trial assessing feasibility.

    University of Ottawa
    Clinical Trials Link

  • 2019

    Dr. Kevin Kuo

    A multicenter study evaluating the reliability and validity of the Rowland Universal Dementia Assessment Scale (RUDAS) and predictors of RUDAS performance in adults with Sickle Cell Disease

    University of Toronto


  • 2018

    Dr. Christine Cserti-Gazdewich

    The Monocyte Monolayer Assay: Enhancing Care for the Untrasfusables

    Blood Transfusion Medicine, Toronto General Hospital

  • 2018

    Dr. Robert Kridel

    Identifying new therapeutic targets for double-hit lymphoma using CRISPR-Cas screens

    Medical Oncology & Hematology Princess Margaret Cancer Centre, Toronto


  • 2017

    Dr. Steven Chan

    Genome-Wide Identification of Synthetic Lethal Genes against TET2 Mutations in Acute Myeloid Leukemia (AML)

    Princess Margaret, University Health Network, Toronto

  • 2017

    Dr. Bertrand Routy

    Influence of gut microbiota on anticancer activity of immuno-therapeutic strategies in patients with multiple myeloma

    McGill University, Montreal


  • 2016

    Dr. Signy Chow

    Next Generation Sequencing of circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) and Monitoring of Clonal Evolution in Multiple Myeloma (MM).

    University Health Network, Toronto

  • 2016

    Dr. Ziad Solh

    Neonatal Outcomes after Transfusion of ABO Non-Identical Blood (Neo-ABO)

    McMaster University, Hamilton, Ontario


  • 2015

    Dr. Yulia Lin

    Setting the benchmark metric for red blood cell transfusion (RBC) to allow for assessment of optimal transfusion care: A pilot quality project at 10 hospitals.

    Sunnybrook Health Sciences Centre and University Health Network, Toronto

  • 2015

    Dr. Ana Nijnik

    Genome-wide Identification of p53-Regulated Genes in Hematopoietic Stem and Progenitor Cells

    McMaster University, Hamilton, Ontario


  • 2014

    Dr. Geerte van Sluis

    A Pilot Study Investigating the Significance of Novel Factor Xa Inhibitor Interactions with Dexamethasone-Containing Regimens for Multiple Myeloma

    University of British Columbia

  • 2014

    Dr. Paul Spagnuolo

    Mitophagy in the development of leukemia stem cell mitochondrial phenotype

    University Waterloo, School of Pharmacy


  • 2013

    Dr. Brent Williams

    Treatment of AML xenografted mice with CD16+NK-92 and anti-CD123 antibody

    Princess Margaret Hospital, Toronto

  • 2013

    Dr. Isaac Odame

    White matter integrity and neurocognition in sickle cell patients

    University of Toronto

  • 2013

    Dr. Nathalie A. Johnson

    The role of FAZ mutations in chemotherapy-resistant lymphomas

    McGill University, Montreal


  • 2012

    Dr. Hubert Tsui

    “Sensing” Hematopoiesis

    University of Toronto

  • 2012

    Dr. Christian Steidl

    Prognostic markers in relapsed Hodgkin lymphoma

    BC Cancer Centre

  • 2012

    Dr. Michael Rauh

    Myeloid-derived suppressor cells as potential novel mediators of Factor VIII tolerance in Hemophilia A

    Queen’s University, Kingston, Ontario